{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T05:37:17Z","timestamp":1794461837046,"version":"4.9.1"},"reference-count":156,"publisher":"The Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To update the \u201cTestosterone Therapy in Men With Androgen Deficiency Syndromes\u201d guideline published in 2010.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>The participants include an Endocrine Society\u2013appointed task force of 10 medical content experts and a clinical practice guideline methodologist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence<\/jats:title>\n                    <jats:p>This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Consensus Process<\/jats:title>\n                    <jats:p>One group meeting, several conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees and members and the cosponsoring organization were invited to review and comment on preliminary drafts of the guideline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone\u2013binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level &amp;gt; 4 ng\/mL, prostate-specific antigen &amp;gt; 3 ng\/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jc.2018-00229","type":"journal-article","created":{"date-parts":[[2018,3,17]],"date-time":"2018-03-17T09:02:51Z","timestamp":1521277371000},"page":"1715-1744","source":"Crossref","is-referenced-by-count":1571,"title":["Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline"],"prefix":"10.1210","volume":"103","author":[{"given":"Shalender","family":"Bhasin","sequence":"first","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P","family":"Brito","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn R","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances J","family":"Hayes","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard N","family":"Hodis","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin M","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Veterans Affairs Puget Sound Health Care System, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J","family":"Snyder","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S","family":"Swerdloff","sequence":"additional","affiliation":[{"name":"Harbor\u2013UCLA Medical Center, Torrance, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick C","family":"Wu","sequence":"additional","affiliation":[{"name":"University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A","family":"Yialamas","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2018,3,17]]},"reference":[{"issue":"7454","key":"2020071622534932500_B1","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"3","key":"2020071622534932500_B2","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1210\/jc.2007-1907","article-title":"A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system","volume":"93","author":"Swiglo","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2020071622534932500_B3","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jclinepi.2014.12.011","article-title":"Guideline panels should not GRADE good practice statements","volume":"68","author":"Guyatt","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"2020071622534932500_B4","doi-asserted-by":"crossref","unstructured":"Ponce OJ , Spencer-BonillaG, Alvarez-VillalobosN, SerranoV, Singh-OspinaN, Rodriguez-GutierrezR, Salcido-MontenegroA, BenkhadraR, ProkopLJ, BhasinS, BritoJP. The efficacy and adverse events of testosterone replacement therapy in hypogonadal men: a systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Endocrinol Metab. 2018;103(5):1745\u20131754.","DOI":"10.1210\/jc.2018-00404"},{"key":"2020071622534932500_B5","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/B978-0-323-29738-7.00019-8","article-title":"Testicular disorders","volume-title":"Williams Textbook of Endocrinology","author":"Matsumoto","year":"2016","edition":"13th ed"},{"key":"2020071622534932500_B6","article-title":"Disorders of the testes and male reproductive system","volume-title":"Harrison\u2019s Principles of Internal Medicine","author":"Bhasin","year":"2015","edition":"19th ed"},{"issue":"6","key":"2020071622534932500_B7","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1210\/jc.2009-2354","article-title":"Task Force: Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline","volume":"95","author":"Bhasin","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2020071622534932500_B8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/andr.12428","article-title":"Contributors to the substantial variation in on-treatment testosterone levels in men receiving transdermal testosterone gels in randomized trials","volume":"6","author":"Bhasin","year":"2018","journal-title":"Andrology"},{"issue":"3","key":"2020071622534932500_B9","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1210\/jc.2008-1902","article-title":"The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men","volume":"94","author":"Brambilla","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2020071622534932500_B10","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1210\/jc.2007-1972","article-title":"Hypothalamic\u2013pituitary\u2013testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study","volume":"93","author":"Wu","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2020071622534932500_B11","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1210\/jc.2007-1245","article-title":"Prevalence of symptomatic androgen deficiency in men","volume":"92","author":"Araujo","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2020071622534932500_B12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0911101","article-title":"Identification of late-onset hypogonadism in middle-aged and elderly men","volume":"363","author":"Wu","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"2020071622534932500_B13","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1206168","article-title":"Gonadal steroids and body composition, strength, and sexual function in men","volume":"369","author":"Finkelstein","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"2020071622534932500_B14","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1172\/JCI84137","article-title":"Gonadal steroid-dependent effects on bone turnover and bone mineral density in men","volume":"126","author":"Finkelstein","year":"2016","journal-title":"J Clin Invest"},{"issue":"9","key":"2020071622534932500_B15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/jama.2012.227","article-title":"Effect of testosterone supplementation with and without a dual 5\u03b1-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial","volume":"307","author":"Bhasin","year":"2012","journal-title":"JAMA"},{"issue":"2","key":"2020071622534932500_B16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1210\/jc.2006-1859","article-title":"The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men","volume":"92","author":"Travison","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2020071622534932500_B17","doi-asserted-by":"crossref","first-page":"e1002313","DOI":"10.1371\/journal.pgen.1002313","article-title":"Genetic determinants of serum testosterone concentrations in men","volume":"7","author":"Ohlsson","year":"2011","journal-title":"PLoS Genet"},{"issue":"6","key":"2020071622534932500_B18","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1210\/jcem-56-6-1278","article-title":"Loss of circadian rhythmicity in blood testosterone levels with aging in normal men","volume":"56","author":"Bremner","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2020071622534932500_B19","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2265.2007.02976.x","article-title":"Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men","volume":"67","author":"Brambilla","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2020071622534932500_B20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2265.2012.04486.x","article-title":"Abrupt decrease in serum testosterone levels after an oral glucose load in men: implications for screening for hypogonadism","volume":"78","author":"Caronia","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2020071622534932500_B21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1439-0272.2012.01296.x","article-title":"S-testosterone decrease after a mixed meal in healthy men independent of SHBG and gonadotrophin levels","volume":"44","author":"Lehtihet","year":"2012","journal-title":"Andrologia"},{"issue":"5 Pt 1","key":"2020071622534932500_B22","first-page":"E658","article-title":"Neuroendocrine-gonadal axis in men: frequent sampling of LH, FSH, and testosterone","volume":"254","author":"Spratt","year":"1988","journal-title":"Am J Physiol"},{"issue":"2","key":"2020071622534932500_B23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1210\/jc.2006-1864","article-title":"Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement","volume":"92","author":"Rosner","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2020071622534932500_B24","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1210\/er.2017-00025","article-title":"A Reappraisal of testosterone\u2019s binding in circulation: physiological and clinical implications","volume":"38","author":"Goldman","year":"2017","journal-title":"Endocr Rev"},{"issue":"7","key":"2020071622534932500_B25","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1210\/jc.2015-4106","article-title":"Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone","volume":"101","author":"Antonio","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2020071622534932500_B26","doi-asserted-by":"crossref","first-page":"E1798","DOI":"10.1210\/jc.2014-2055","article-title":"Sex hormone binding globulin deficiency due to a homozygous missense mutation","volume":"99","author":"Vos","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2020071622534932500_B27","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.juro.2011.11.095","article-title":"Performance of total testosterone measurement to predict free testosterone for the biochemical evaluation of male hypogonadism","volume":"187","author":"Anawalt","year":"2012","journal-title":"J Urol"},{"key":"2020071622534932500_B28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.mce.2014.09.001","article-title":"A multi-step, dynamic allosteric model of testosterone\u2019s binding to sex hormone binding globulin","volume":"399","author":"Zakharov","year":"2015","journal-title":"Mol Cell Endocrinol"},{"issue":"10","key":"2020071622534932500_B29","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1210\/jcem.84.10.6079","article-title":"A critical evaluation of simple methods for the estimation of free testosterone in serum","volume":"84","author":"Vermeulen","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"Pt 2","key":"2020071622534932500_B30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1258\/acb.2008.008171","article-title":"Predictive accuracy and sources of variability in calculated free testosterone estimates","volume":"46","author":"Sartorius","year":"2009","journal-title":"Ann Clin Biochem"},{"issue":"4","key":"2020071622534932500_B31","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1210\/jc.2016-2935","article-title":"Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe","volume":"102","author":"Travison","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2020071622534932500_B32","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1210\/jc.2011-1137","article-title":"Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis","volume":"96","author":"Araujo","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2020071622534932500_B33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40985-015-0012-1","article-title":"Screening and overdiagnosis: public health implications","volume":"36","author":"Bulliard","year":"2015","journal-title":"Public Health Rev"},{"issue":"8","key":"2020071622534932500_B34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/jcp.26.8.555","article-title":"Current trends and problems in health screening","volume":"26","author":"Wilson","year":"1973","journal-title":"J Clin Pathol"},{"key":"2020071622534932500_B35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.01.038","article-title":"Testosterone suppression in opioid users: a systematic review and meta-analysis","volume":"149","author":"Bawor","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"2020071622534932500_B36","doi-asserted-by":"crossref","first-page":"639","DOI":"10.7326\/0003-4819-106-4-639","article-title":"Serum testosterone levels during chronic glucocorticoid therapy","volume":"106","author":"Reid","year":"1987","journal-title":"Ann Intern Med"},{"issue":"6","key":"2020071622534932500_B37","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/j.juro.2013.06.010","article-title":"Anabolic steroid induced hypogonadism in young men","volume":"190","author":"Coward","year":"2013","journal-title":"J Urol"},{"issue":"5","key":"2020071622534932500_B38","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/add.12850","article-title":"Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids: an under-recognized problem","volume":"110","author":"Kanayama","year":"2015","journal-title":"Addiction"},{"issue":"8","key":"2020071622534932500_B39","doi-asserted-by":"crossref","first-page":"e0161208","DOI":"10.1371\/journal.pone.0161208","article-title":"Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation: a case-control study","volume":"11","author":"Rasmussen","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"2020071622534932500_B40","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/j.1939-4640.1999.tb02562.x","article-title":"Serum dihydrotestosterone and testosterone concentrations in human immunodeficiency virus-infected men with and without weight loss","volume":"20","author":"Arver","year":"1999","journal-title":"J Androl"},{"issue":"3","key":"2020071622534932500_B41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/edrv.23.3.0465","article-title":"Sex steroids and the construction and conservation of the adult skeleton","volume":"23","author":"Riggs","year":"2002","journal-title":"Endocr Rev"},{"issue":"9","key":"2020071622534932500_B42","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1053\/meta.2000.8625","article-title":"Validation of a screening questionnaire for androgen deficiency in aging males","volume":"49","author":"Morley","year":"2000","journal-title":"Metabolism"},{"issue":"1","key":"2020071622534932500_B43","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.eururo.2004.01.009","article-title":"The Aging Males\u2019 Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency","volume":"46","author":"Moore","year":"2004","journal-title":"Eur Urol"},{"issue":"6","key":"2020071622534932500_B44","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1046\/j.1365-2265.2000.01152.x","article-title":"Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men","volume":"53","author":"Smith","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2020071622534932500_B45","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.jsxm.2016.09.006","article-title":"Psychometric evaluation of the Hypogonadism Impact of Symptoms Questionnaire","volume":"13","author":"Gelhorn","year":"2016","journal-title":"J Sex Med"},{"issue":"4","key":"2020071622534932500_B46","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/ijcp.12542","article-title":"Establishing the content validity of the Sexual Arousal, Interest, and Drive Scale and the Hypogonadism Energy Diary","volume":"69","author":"Hayes","year":"2015","journal-title":"Int J Clin Pract"},{"issue":"17","key":"2020071622534932500_B47","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1056\/NEJMc1611875","article-title":"More on biotin treatment mimicking Graves\u2019 disease","volume":"375","author":"Trambas","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"2020071622534932500_B48","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrendo.2015.112","article-title":"Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism\u2014pathogenesis, diagnosis and treatment","volume":"11","author":"Boehm","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"2020071622534932500_B49","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/cen.13015","article-title":"The prevalence of structural pituitary abnormalities by MRI scanning in men presenting with isolated hypogonadotrophic hypogonadism","volume":"84","author":"Dalvi","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2020071622534932500_B50","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/01.GIM.0000095626.54201.D0","article-title":"Klinefelter syndrome: expanding the phenotype and identifying new research directions","volume":"5","author":"Simpson","year":"2003","journal-title":"Genet Med"},{"issue":"11","key":"2020071622534932500_B51","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1056\/NEJM198509123131102","article-title":"Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism","volume":"313","author":"Finkel","year":"1985","journal-title":"N Engl J Med"},{"issue":"12","key":"2020071622534932500_B52","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1111\/j.1743-6109.2011.02497.x","article-title":"The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism","volume":"8","author":"Giagulli","year":"2011","journal-title":"J Sex Med"},{"issue":"3","key":"2020071622534932500_B53","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.juro.2015.10.083","article-title":"Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study","volume":"195","author":"Brock","year":"2016","journal-title":"J Urol"},{"issue":"6","key":"2020071622534932500_B54","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1210\/jc.2002-021058","article-title":"AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function","volume":"88","author":"Steidle","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2020071622534932500_B55","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1210\/jc.2016-1645","article-title":"Testosterone treatment and sexual function in older men with low testosterone Levels","volume":"101","author":"Cunningham","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2020071622534932500_B56","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1001\/jama.2015.8881","article-title":"Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial","volume":"314","author":"Basaria","year":"2015","journal-title":"JAMA"},{"issue":"9","key":"2020071622534932500_B57","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7326\/0003-4819-151-9-200911030-00150","article-title":"Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis","volume":"151","author":"Tsertsvadze","year":"2009","journal-title":"Ann Intern Med"},{"issue":"10","key":"2020071622534932500_B58","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/0003-4819-157-10-201211200-00004","article-title":"Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial","volume":"157","author":"Spitzer","year":"2012","journal-title":"Ann Intern Med"},{"issue":"1","key":"2020071622534932500_B59","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1743-6109.2010.01956.x","article-title":"Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study)","volume":"8","author":"Buvat","year":"2011","journal-title":"J Sex Med"},{"issue":"8","key":"2020071622534932500_B60","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1210\/jc.2014-4434","article-title":"Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial","volume":"100","author":"Paduch","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2020071622534932500_B61","first-page":"3578","article-title":"Testosterone replacement therapy improves mood in hypogonadal men\u2014a clinical research center study","volume":"81","author":"Wang","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071622534932500_B62","volume-title":"Testosterone and Aging: Clinical Research Directions","author":"Liverman","year":"2004"},{"issue":"2","key":"2020071622534932500_B63","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/JCP.0b013e3181d207ca","article-title":"Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment","volume":"30","author":"Pope","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"2020071622534932500_B64","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1176\/appi.ajp.159.3.456","article-title":"Low testosterone levels in elderly men with dysthymic disorder","volume":"159","author":"Seidman","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"2","key":"2020071622534932500_B65","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/archpsyc.61.2.162","article-title":"Increased incidence of diagnosed depressive illness in hypogonadal older men","volume":"61","author":"Shores","year":"2004","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"2020071622534932500_B66","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/JCP.0b013e3181a39137","article-title":"Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial","volume":"29","author":"Seidman","year":"2009","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"2020071622534932500_B67","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.4088\/JCP.08m04478","article-title":"A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression)","volume":"70","author":"Shores","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"2020071622534932500_B68","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa1506119","article-title":"Effects of testosterone treatment in older men","volume":"374","author":"Snyder","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2020071622534932500_B69","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamainternmed.2016.9539","article-title":"Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial","volume":"177","author":"Snyder","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"8","key":"2020071622534932500_B70","first-page":"2670","article-title":"Effects of testosterone replacement in hypogonadal men","volume":"85","author":"Snyder","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2020071622534932500_B71","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1530\/eje.1.01920","article-title":"Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men","volume":"152","author":"Aminorroaya","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2020071622534932500_B72","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2011-3045","article-title":"Osteoporosis in men: an Endocrine Society clinical practice guideline","volume":"97","author":"Watts","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2020071622534932500_B73","first-page":"407","article-title":"Testosterone replacement increases fat-free mass and muscle size in hypogonadal men","volume":"82","author":"Bhasin","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2020071622534932500_B74","first-page":"3469","article-title":"Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men\u2014a clinical research center study","volume":"81","author":"Brodsky","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2020071622534932500_B75","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1210\/jc.2003-031492","article-title":"Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men","volume":"89","author":"Woodhouse","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2020071622534932500_B76","doi-asserted-by":"crossref","first-page":"E1172","DOI":"10.1152\/ajpendo.2001.281.6.E1172","article-title":"Testosterone dose-response relationships in healthy young men","volume":"281","author":"Bhasin","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"2020071622534932500_B77","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1210\/jc.2004-1184","article-title":"Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle","volume":"90","author":"Bhasin","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2020071622534932500_B78","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/andr.12284","article-title":"Testosterone vs. aromatase inhibitor in older men with low testosterone: effects on cardiometabolic parameters","volume":"5","author":"Dias","year":"2017","journal-title":"Andrology"},{"issue":"2","key":"2020071622534932500_B79","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1210\/jc.2009-1251","article-title":"Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study","volume":"95","author":"Srinivas-Shankar","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2020071622534932500_B80","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1000485","article-title":"Adverse events associated with testosterone administration","volume":"363","author":"Basaria","year":"2010","journal-title":"N Engl J Med"},{"issue":"16","key":"2020071622534932500_B81","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa054629","article-title":"DHEA in elderly women and DHEA or testosterone in elderly men","volume":"355","author":"Nair","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"2020071622534932500_B82","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2007.51","article-title":"Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial","volume":"299","author":"Emmelot-Vonk","year":"2008","journal-title":"JAMA"},{"issue":"3","key":"2020071622534932500_B83","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1210\/jc.2004-1933","article-title":"Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T","volume":"90","author":"Page","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2020071622534932500_B84","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S2213-8587(16)30102-4","article-title":"Effects of long-term testosterone administration on cognition in older men with low or low-to-normal testosterone concentrations: a prespecified secondary analysis of data from the randomised, double-blind, placebo-controlled TEAAM trial","volume":"4","author":"Huang","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2020071622534932500_B85","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jama.2016.21044","article-title":"Testosterone treatment and cognitive function in older men with low testosterone and age-associated memory impairment","volume":"317","author":"Resnick","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"2020071622534932500_B86","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1210\/jc.2009-2575","article-title":"Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis","volume":"95","author":"Fern\u00e1ndez-Balsells","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2020071622534932500_B87","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-6196(11)60964-6","article-title":"Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"82","author":"Haddad","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"2020071622534932500_B88","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/gerona\/60.11.1451","article-title":"Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials","volume":"60","author":"Calof","year":"2005","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"3","key":"2020071622534932500_B89","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1210\/jc.2007-1692","article-title":"Effects of graded doses of testosterone on erythropoiesis in healthy young and older men","volume":"93","author":"Coviello","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2020071622534932500_B90","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1210\/er.2001-0025","article-title":"Androgens and coronary artery disease","volume":"24","author":"Wu","year":"2003","journal-title":"Endocr Rev"},{"issue":"16","key":"2020071622534932500_B91","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2011.07.019","article-title":"High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (osteoporotic fractures in men) study in Sweden","volume":"58","author":"Ohlsson","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2020071622534932500_B92","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1210\/jc.2014-3934","article-title":"Endogenous testosterone and its relationship to preclinical and clinical measures of cardiovascular disease in the atherosclerosis risk in communities study","volume":"100","author":"Srinath","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2020071622534932500_B93","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/cen.12997","article-title":"Association of endogenous testosterone with subclinical atherosclerosis in men: the multi-ethnic study of atherosclerosis","volume":"84","author":"Khazai","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2020071622534932500_B94","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1530\/EJE-11-0447","article-title":"Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study","volume":"165","author":"Corona","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"2020071622534932500_B95","first-page":"1502","article-title":"Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T","volume-title":"J Clin Endocrinol Metab","author":"Page","year":"2005"},{"issue":"17","key":"2020071622534932500_B96","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.2013.280386","article-title":"Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels","volume":"310","author":"Vigen","year":"2013","journal-title":"JAMA"},{"issue":"40","key":"2020071622534932500_B97","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1093\/eurheartj\/ehv346","article-title":"Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men","volume":"36","author":"Sharma","year":"2015","journal-title":"Eur Heart J"},{"issue":"5","key":"2020071622534932500_B98","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.amjcard.2015.11.063","article-title":"Impact of testosterone replacement therapy on myocardial infarction, stroke, and death in men with low testosterone concentrations in an integrated health care system","volume":"117","author":"Anderson","year":"2016","journal-title":"Am J Cardiol"},{"issue":"6","key":"2020071622534932500_B99","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1530\/EJE-13-0321","article-title":"Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes","volume":"169","author":"Muraleedharan","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2020071622534932500_B100","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jamainternmed.2016.9546","article-title":"Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency","volume":"177","author":"Cheetham","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"1","key":"2020071622534932500_B101","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-014-0211-5","article-title":"Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis","volume":"12","author":"Borst","year":"2014","journal-title":"BMC Med"},{"issue":"3","key":"2020071622534932500_B102","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.amjmed.2016.09.017","article-title":"Cardiovascular risks of exogenous testosterone use among men: a systematic review and meta-analysis","volume":"130","author":"Alexander","year":"2017","journal-title":"Am J Med"},{"key":"2020071622534932500_B103","unstructured":"Food and Drug Administration. Citizen petition denial response from FDA CDER to public citizen. Available at: www.regulations.gov\/document?D=FDA-2014-P-0258-0003. Accessed 4 September 2017."},{"key":"2020071622534932500_B104","unstructured":"European Medicines Agency. No consistent evidence of an increased risk of heart problems with testosterone medicines. Available at: www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2014\/11\/WC500177618.pdf. Accessed 10 January 2018."},{"issue":"8","key":"2020071622534932500_B105","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.mayocp.2015.05.012","article-title":"Risk of venous thromboembolism in men receiving testosterone therapy","volume":"90","author":"Baillargeon","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"2020071622534932500_B106","doi-asserted-by":"crossref","first-page":"i5968","DOI":"10.1136\/bmj.i5968","article-title":"Testosterone treatment and risk of venous thromboembolism: population based case-control study","volume":"355","author":"Martinez","year":"2016","journal-title":"BMJ"},{"issue":"6","key":"2020071622534932500_B107","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1177\/1076029615619486","article-title":"Thrombophilia in 67 patients with thrombotic events after starting testosterone therapy","volume":"22","author":"Glueck","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"2020071622534932500_B108","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/j.1939-4640.2003.tb02676.x","article-title":"Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan","volume":"24","author":"Bhasin","year":"2003","journal-title":"J Androl"},{"issue":"3","key":"2020071622534932500_B109","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jnci\/djm323","article-title":"Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies","volume":"100","author":"Roddam","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"2020071622534932500_B110","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/jnci\/88.16.1118","article-title":"Prospective study of sex hormone levels and risk of prostate cancer","volume":"88","author":"Gann","year":"1996","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2020071622534932500_B111","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1158\/1055-9965.EPI-04-0371","article-title":"Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era","volume":"14","author":"Platz","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"2020071622534932500_B112","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1200\/JCO.2000.18.4.847","article-title":"Hormonal predictors of prostate cancer: a meta-analysis","volume":"18","author":"Shaneyfelt","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020071622534932500_B113","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"issue":"3","key":"2020071622534932500_B114","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0022-5347(17)54531-0","article-title":"The response of metastatic adenocarcinoma of the prostate to exogenous testosterone","volume":"126","author":"Fowler","year":"1981","journal-title":"J Urol"},{"key":"2020071622534932500_B115","unstructured":"U.S. Preventive Services Task Force. Final recommendation statement. Prostate cancer: screening. Available at: www.uspreventiveservicestaskforce.org\/Page\/Document\/RecommendationStatementFinal\/prostate-cancer-screening. Accessed 4 December 2017."},{"issue":"4","key":"2020071622534932500_B116","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/ijc.31102","article-title":"Summary statement on screening for prostate cancer in Europe","volume":"142","author":"Heijnsdijk","year":"2018","journal-title":"Int J Cancer"},{"issue":"4","key":"2020071622534932500_B117","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.juro.2016.04.069","article-title":"Testosterone therapy in patients with treated and untreated prostate cancer: impact on oncologic outcomes","volume":"196","author":"Ory","year":"2016","journal-title":"J Urol"},{"issue":"13","key":"2020071622534932500_B118","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMsb1616281","article-title":"Prostate cancer screening\u2014a perspective on the current state of the evidence","volume":"376","author":"Pinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"2020071622534932500_B119","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.urology.2014.02.035","article-title":"Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer","volume":"83","author":"Ankerst","year":"2014","journal-title":"Urology"},{"issue":"2","key":"2020071622534932500_B120","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.juro.2016.08.092","article-title":"Prognostic significance of digital rectal examination and prostate specific antigen in the prostate, lung, colorectal and ovarian (PLCO) cancer screening arm","volume":"197","author":"Halpern","year":"2017","journal-title":"J Urol"},{"key":"2020071622534932500_B121","unstructured":"Halpern JA , OromendiaC, ShoagJE, MittalS, CosianoMF, BallmanKV, VickersAJ, HuJC. Utility of digital rectal examination as an adjunct to prostate specific antigen in the detection of clinically significant prostate cancer. J Urol. 2017;S0022-5347(17)77762-2."},{"issue":"22","key":"2020071622534932500_B122","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level \u22644.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N Engl J Med"},{"issue":"6 Pt 1","key":"2020071622534932500_B123","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0022-5347(17)32300-5","article-title":"Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves","volume":"152","author":"Catalona","year":"1994","journal-title":"J Urol"},{"issue":"2","key":"2020071622534932500_B124","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bju.13578","article-title":"Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men","volume":"119","author":"Debruyne","year":"2017","journal-title":"BJU Int"},{"key":"2020071622534932500_B125","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.urology.2015.11.006","article-title":"The relationship between testosterone-replacement therapy and lower urinary tract symptoms: a systematic review","volume":"88","author":"Kathrins","year":"2016","journal-title":"Urology"},{"issue":"6","key":"2020071622534932500_B126","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/andr.262","article-title":"Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study","volume":"2","author":"Rastrelli","year":"2014","journal-title":"Andrology"},{"issue":"1","key":"2020071622534932500_B127","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1210\/endo-26-1-26","article-title":"A comparative study of the metabolic effects of testosterone propionate in normal men and women and in eunuchoidism","volume":"26","author":"Kenyon","year":"1940","journal-title":"Endocrinology"},{"issue":"8","key":"2020071622534932500_B128","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1210\/jc.2010-3012","article-title":"Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts","volume":"96","author":"Bhasin","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2020071622534932500_B129","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1530\/eje.1.02241","article-title":"The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study","volume":"155","author":"Mohr","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2020071622534932500_B130","first-page":"2647","article-title":"Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age","volume":"84","author":"Snyder","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2020071622534932500_B131","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jamainternmed.2016.9540","article-title":"Association of testosterone levels with anemia in older men: a controlled clinical trial","volume":"177","author":"Roy","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"7","key":"2020071622534932500_B132","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.2016.21043","article-title":"Testosterone treatment and coronary artery plaque volume in older men with low testosterone","volume":"317","author":"Budoff","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"2020071622534932500_B133","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/QAI.0000000000000821","article-title":"Longitudinal changes over 10 years in free testosterone among HIV-infected and HIV-uninfected men","volume":"71","author":"Slama","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"2020071622534932500_B134","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1086\/317457","article-title":"Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy","volume":"31","author":"Rietschel","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2020071622534932500_B135","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S1473-3099(02)00441-3","article-title":"Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis","volume":"2","author":"Kong","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"2020071622534932500_B136","doi-asserted-by":"crossref","unstructured":"Johns K , BeddallMJ, CorrinRC. Anabolic steroids for the treatment of weight loss in HIV-infected individuals. Cochrane Database Syst Rev. 2005; (4):CD005483.","DOI":"10.1002\/14651858.CD002836.pub2"},{"issue":"6","key":"2020071622534932500_B137","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/jama.283.6.763","article-title":"Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels","volume":"283","author":"Bhasin","year":"2000","journal-title":"JAMA"},{"issue":"1","key":"2020071622534932500_B138","first-page":"60","article-title":"Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men","volume":"85","author":"Grinspoon","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2020071622534932500_B139","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archpsyc.57.2.141","article-title":"A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms","volume":"57","author":"Rabkin","year":"2000","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"2020071622534932500_B140","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1210\/jc.2004-0804","article-title":"Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes","volume":"89","author":"Dhindsa","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"6 Pt 1","key":"2020071622534932500_B141","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2605.2010.01117.x","article-title":"Type 2 diabetes mellitus and testosterone: a meta-analysis study","volume":"34","author":"Corona","year":"2011","journal-title":"Int J Androl"},{"issue":"6","key":"2020071622534932500_B142","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1530\/eje.1.02166","article-title":"Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes","volume":"154","author":"Kapoor","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2020071622534932500_B143","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.2337\/dc11-1484","article-title":"Response to comment on: Jones et al. Testosterone replacement in hypogonadal men with type 2 diabetes and\/or metabolic syndrome (the TIMES2 Study). Diabetes Care 2011;34:828\u2013837","volume":"34","author":"Jones","year":"2011","journal-title":"Diabetes Care"},{"issue":"1","key":"2020071622534932500_B144","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2337\/dc15-1518","article-title":"Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes","volume":"39","author":"Dhindsa","year":"2016","journal-title":"Diabetes Care"},{"issue":"8","key":"2020071622534932500_B145","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.2337\/dc13-2845","article-title":"Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial","volume":"37","author":"Gianatti","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"2020071622534932500_B146","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/cen.12664","article-title":"Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta-analysis of randomized controlled clinical trials","volume":"83","author":"Grossmann","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"2020071622534932500_B147","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1210\/JC.2015-1542","article-title":"Serum testosterone (T) level variability in T gel-treated older hypogonadal men: treatment monitoring implications","volume":"100","author":"Swerdloff","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"2020071622534932500_B148","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199210223271701","article-title":"The effect of finasteride in men with benign prostatic hyperplasia","volume":"327","author":"Gormley","year":"1992","journal-title":"N Engl J Med"},{"issue":"4","key":"2020071622534932500_B149","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0090-4295(93)90364-G","article-title":"Analysis of variation in prostate-specific antigen values","volume":"42","author":"Riehmann","year":"1993","journal-title":"Urology"},{"issue":"1","key":"2020071622534932500_B150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncpuro0702","article-title":"The responsible use of antibiotics for an elevated PSA level","volume":"4","author":"Scardino","year":"2007","journal-title":"Nat Clin Pract Urol"},{"issue":"3","key":"2020071622534932500_B151","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1210\/er.2013-1058","article-title":"Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement","volume":"35","author":"Pope","year":"2014","journal-title":"Endocr Rev"},{"issue":"1093","key":"2020071622534932500_B152","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/postgradmedj-2016-134299","article-title":"The effects of opioids on the endocrine system: an overview","volume":"92","author":"Ali","year":"2016","journal-title":"Postgrad Med J"},{"issue":"3","key":"2020071622534932500_B153","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.drugalcdep.2006.05.027","article-title":"Low bone density in patients receiving methadone maintenance treatment","volume":"85","author":"Kim","year":"2006","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"2020071622534932500_B154","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00774-016-0755-x","article-title":"Opioids increase hip fracture risk: a meta-analysis","volume":"35","author":"Ping","year":"2017","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"2020071622534932500_B155","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11606-016-3940-7","article-title":"Who gets testosterone? Patient characteristics associated with testosterone prescribing in the Veteran Affairs system: a cross-sectional study","volume":"32","author":"Jasuja","year":"2017","journal-title":"J Gen Intern Med"},{"issue":"2","key":"2020071622534932500_B156","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.j.pain.0000460308.86819.aa","article-title":"Effects of testosterone replacement in men with opioid-induced androgen deficiency: a randomized controlled trial","volume":"156","author":"Basaria","year":"2015","journal-title":"Pain"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/103\/5\/1715\/24795187\/jc.2018-00229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/103\/5\/1715\/24795187\/jc.2018-00229.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T13:20:40Z","timestamp":1693574440000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/103\/5\/1715\/4939465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,17]]},"references-count":156,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2018-00229","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732878989.793556567","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.732878989.793576594","asserted-by":"object"}]},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,5]]},"published":{"date-parts":[[2018,3,17]]}}}